Find below new deal announcement where De Brauw was lead counsel for Achmea during the same of Independer.nl N.V.

Client name
Achmea B.V.

Other parties involved
de Persgroep Nederland B.V., Independer.nl N.V.

Nature of transaction
De Brauw acted as lead counsel during the sale of Independer.nl N.V., the Dutch online comparison and advice platform for insurance policies, banking products, mortgages and energy contracts, by Achmea B.V. to de Persgroep Nederland B.V.

Value of transaction
Undisclosed

Date deal

DWF Manchester has advised LPW Technology, a leading manufacturer of ultra-clean Additive Manufacturing (AM) metal powders used for 3D printing, on its sale to USA industry giant, Carpenter Technology Corporation.

The Widnes-based business - which also has a presence near Pittsburgh, Pennsylvania - provides state-of-the-art metal powder to clients all over the world to support 3D modelling production. LPW has also recently invested in automisation and software capability and is at the forefront of metal powder Additive Manufacturing.

Sanofi and Advent International announced on October 1, 2018, that they had completed the sale of Zentiva, Sanofi’s European generics business, to funds managed by Advent International for €1.9 billion, effective September 30, 2018.

Schulte advised Noventis, an electronic payments network focused on optimizing payment delivery for bills and invoices to commercial entities, as payments regulatory counsel, in its sale to WEX Inc., a leading provider of corporate payments solutions. The transaction will expand WEX’s corporate payments business while also enhancing Noventis’ offerings to its customers. The transaction was announced on Oct. 22, 2018 and is expected to close the first half of 2019.

International legal practice Osborne Clarke has advised Caledonia Investments plc, on its £152.5m sale of Choice Care Group (“Choice”), a leading provider of residential and supported living services, to iCon Infrastructure Partners, IV L.P.

Charles Russell Speechlys has advised the members of independent business law firm Turner Parkinson LLP on its acquisition by Knights.

PARIS – McDermott Will & Emery advised H-Immune Therapeutics, a biotechnology company in its development phase and specializing in new therapeutic approaches based on the FULLY HUMAN monoclonal antibodies the field of immuno-oncology, in connection with the sale of their shares to HiFiBio Therapeutics, a pioneer company and one of the world leaders proposing a complete innovative technology creating unparalleled possibilities for the discovery of new therapeutic antibodies against complex targets.